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Molecular Biology SelectThe central importance of the tumor suppressor Retinoblastoma protein (Rb) in cell-cycle progressionmakes
its regulation a focal point for diverse biological processes, as evidenced by recent work described in this
issue’s Molecular Biology Select. These findings reveal new insight into Rb’s involvement in tissue regener-
ation and differentiation, as well as previously unrecognized mechanisms of Rb regulation.Dedifferentiated myocytes redifferentiate and fuse
into existing muscles in vivo (visualized with green
fluorescent protein).Short-Term Inactivation, Lasting Benefits
Tissue regeneration in mammals is greatly restricted, whereas
many other types of vertebrates display astonishing feats of tissue
replacement, including regrowth of major structures such as
limbs. According to new findings by Pajcini et al. (2010), mamma-
lian innovations in the realm of tumor suppression are one factor
that is likely to contribute to this pronounced deficiency. The
authors show that combined inactivation of the tumor suppressors
retinoblastoma (Rb) and ARF reverses the differentiation of mouse
muscle cells, turning postmitotic cells into proliferating myoblasts,
and when these induced myoblasts are transplanted into donor
mice they successfully fuse into existing myofibers. Prior work in
newts has shown that Rb phosphorylation, which inactivates the
protein, promotes the reentry of myotubes into the cell cycle, a crit-
ical initiating event in limb regeneration. The inspiration to addition-
ally inactivate ARF was motivated by available evidence suggesting
its potential exclusivity to mammals and birds, and thus the authorsreasoned that ARF might be particularly important in mediating differences in regeneration potential between
vertebrate species. Could a similar strategy of Rb and ARF inactivation be used to promote cell-cycle entry of
endogenous cells for regeneration therapy? Although this remains to be seen, the observation that only tran-
sient inactivation of these tumor suppressors is needed for successful creation of regenerative cells may go
some way toward allaying concerns that such an approach would invariably promote cancer. Future efforts
are also likely to address whether this intervention triggers cell-cycle reentry for a range of mammalian cell
types.
K.V. Pajcini et al. (2010). Cell Stem Cell 7, 198–213.Deletion of Rb in the embryo proper using Meox2-
Cre reduces the level of calcified bone as detected
by Alizarin Red staining. Image courtesy of J. Lees.Fat Chance for Bone Formation
Previous in vitro studies suggested that Rb plays a critical role in the
decision of meschenchymal cells to become adipocyte or bone
cells, but in vivo evidence for this hypothesis has been lacking.
Calo et al. (2010) now show that Rb gives meschenchymal cells
the extra nudge they need to commit to becoming bone-forming
osteoblasts. Without Rb, these cells are more likely to differentiate
into brown fat cells, leading to reduced levels of calcified bones
and increased levels of brown adipose tissue in mice. To sort out
how Rb regulates the fate of the meschenchymal cells during devel-
opment, the authors engineered mice with the RB1 gene and/or
the p53 gene deleted only in uncommitted meschenchymal cells.
As expected, animals missing the tumor suppressor p53 develop multiple types of tumors, including osteosar-
comas. Combining the p53mutation with a deletion of oneRB1 allele increases the frequency of osteosarcomas,
whereas deletion of both RB1 alleles shifts the tumor distribution away from osteosarcomas towards brown fat
tumors. Thus, Rb regulates the fate of meschenchymal cells in a dose-dependent manner. These results are
surprising given that the majority of human osteosarcomas contain RB1 mutations. The authors speculate
that osteosarcoma tumors most likely arise from cells already committed to becoming osteoblasts, and muta-
tions in RB1 promote dedifferentiation of these cells and thus tumorigenesis.
E. Calo et al. (2010). Nature. Published online August 4, 2010. 10.1038/nature09264.Cell 142, September 3, 2010 ª2010 Elsevier Inc. 653
X-ray crystal structure of Rb (magenta) in complex
with the PP1 catalytic domain (gray). Image cour-
tesy of S. Rubin.Rb Gets Caught in a Custody Battle
Rb is caught in a tug-of-war between cyclin-dependent kinases
(Cdks) that inactivate it by phosphorylation to permit cell-cycle
progression and phosphatases that remove the modification
to promote cell-cycle arrest. New findings of Hirschi et al. (2010)
demonstrate that this conflict is waged over the same binding
interface of Rb. They provide structural evidence that the phospha-
tase PP1 interacts with Rb in a region previously shown critical for
the interaction of Rb with Cdks. They further show that PP1 can
suppress the activity of Cdk2-cyclin A toward Rb to block cell-
cycle progression in a human osteosarcoma cell line, and that
the complex of PP1 and Rb appears to be stable, or at least
more prevalent, at mitotic exit. Among the interesting questions
this work raises is, what factors determine the outcome of PP1
and Cdk competition? The authors propose that concentration
and subcellular localization of the competing proteins likely play
a role, but it remains unclear how this molecular dispute is settled
under specific biological circumstances, for example after DNA
damage.
A. Hirschi et al. (2010). Nat. Struct. Mol. Bio. Published online August
8, 2010. 10.1038/nsmb.1868.NMRT structure with RCC peptide modeled in the
active site. Image courtesy of I. Macara.Methylation Moves to the Front of the Line
Although first reported more than 30 years ago, methylation
of protein N termini (a-N-methylation) remains a poorly understood
proteinmodification. Thus, the recent identification by Schaner-Too-
ley et al. (2010) of an enzyme that catalyzes the reaction promises to
accelerate understanding of the modification’s functions. The
authors use methylation of a known target of a-N-methylation called
RCC1 (a Ran guanine nucleotide exchange factor) as an indicator of
the presence or absence of the enzymatic activity from fractionated
HeLa cell nuclear extracts. Fractions with methyltransferase activity
were subjected tomass spectrometry, leading to the identification of
the methyltransferase responsible, which the authors name NMRT
(N-terminal RCC1 methyltransferase). The NMRT crystal structure
facilitated themodeling of substrate recognition, and further analysis
defining the consensus sequence for target recognition suggested
Rb as a potential substrate. Subsequent assays provide evidence
that Rb is modified by a-N-methylation, at least in some cell types.
a-N-methylation of RCC1 promotes stable association with chro-
matin, and loss of NMRT or the absence of the RCC1 methylation results in defects in mitosis. In contrast, the
purpose of Rb a-N-methylation remains a tantalizing mystery. Regardless of whether Rb a-N-methylation is rele-
vant to its roles in cell-cycle control, the discovery of NMRT opens a door through which others will likely follow.
Are there other a-N-methyltransferases? And if so, is their substrate specificity similar to NMRT? The answermay
be an indicator of whether this modification is an exotic posttranslational event or might instead be considerably
more common than previously appreciated. Another compelling question is whether there are a-N-demethylases
that reverse the modification.
C.E. Schaner-Tooley et al. (2010). Nature. Published online July 29, 2010. 10.1038/nature09343.
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